Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 571 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR EMA Recommends Extension of Indications for Avelumab December 17, 2020 Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis,... February 10, 2026 Young Adult Cancer Awareness Week: Recognizing Adolescent and Young Adults Cancer... April 5, 2021 First Prospective Description of Familial EGFR-mutated Lung Cancer August 23, 2023 Load more HOT NEWS FDA Approves Fruquintinib for Patients with Refractory Metastatic Colorectal Cancer Childhood cancer survivors at greater risk of ill health New on NCI’s Websites for December 2020 Teclistamab Shows Promise for People with Heavily Pretreated Multiple Myeloma
